Skip to main content

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature.

Publication ,  Journal Article
Palli, R; Seaton, KE; Piepenbrink, MS; Hural, J; Goepfert, PA; Laher, F; Buchbinder, SP; Churchyard, G; Gray, GE; Robinson, HL; Huang, Y ...
Published in: Sci Rep
August 3, 2020

Efficacious HIV-1 vaccination requires elicitation of long-lived antibody responses. However, our understanding of how different vaccine types elicit durable antibody responses is lacking. To assess the impact of vaccine type on antibody responses, we measured IgG isotypes against four consensus HIV antigens from 2 weeks to 10 years post HIV-1 vaccination and used mixed effects models to estimate half-life of responses in four human clinical trials. Compared to protein-boosted regimens, half-lives of gp120-specific antibodies were longer but peak magnitudes were lower in Modified Vaccinia Ankara (MVA)-boosted regimens. Furthermore, gp120-specific B cell transcriptomics from MVA-boosted and protein-boosted vaccines revealed a distinct signature at a peak (2 weeks after last vaccination) including CD19, CD40, and FCRL2-5 activation along with increased B cell receptor signaling. Additional analysis revealed contributions of RIG-I-like receptor pathway and genes such as SMAD5 and IL-32 to antibody durability. Thus, this study provides novel insights into vaccine induced antibody durability and B-cell receptor signaling.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sci Rep

DOI

EISSN

2045-2322

Publication Date

August 3, 2020

Volume

10

Issue

1

Start / End Page

13031

Location

England

Related Subject Headings

  • Vaccinia virus
  • Vaccination
  • Signal Transduction
  • Receptors, Antigen, B-Cell
  • Lymphocyte Activation
  • Linear Models
  • Immunization, Secondary
  • Humans
  • Half-Life
  • HIV-1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Palli, R., Seaton, K. E., Piepenbrink, M. S., Hural, J., Goepfert, P. A., Laher, F., … Thakar, J. (2020). Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Sci Rep, 10(1), 13031. https://doi.org/10.1038/s41598-020-69007-w
Palli, Rohith, Kelly E. Seaton, Michael S. Piepenbrink, John Hural, Paul A. Goepfert, Fatima Laher, Susan P. Buchbinder, et al. “Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature.Sci Rep 10, no. 1 (August 3, 2020): 13031. https://doi.org/10.1038/s41598-020-69007-w.
Palli R, Seaton KE, Piepenbrink MS, Hural J, Goepfert PA, Laher F, et al. Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Sci Rep. 2020 Aug 3;10(1):13031.
Palli, Rohith, et al. “Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature.Sci Rep, vol. 10, no. 1, Aug. 2020, p. 13031. Pubmed, doi:10.1038/s41598-020-69007-w.
Palli R, Seaton KE, Piepenbrink MS, Hural J, Goepfert PA, Laher F, Buchbinder SP, Churchyard G, Gray GE, Robinson HL, Huang Y, Janes H, Kobie JJ, Keefer MC, Tomaras GD, Thakar J. Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Sci Rep. 2020 Aug 3;10(1):13031.

Published In

Sci Rep

DOI

EISSN

2045-2322

Publication Date

August 3, 2020

Volume

10

Issue

1

Start / End Page

13031

Location

England

Related Subject Headings

  • Vaccinia virus
  • Vaccination
  • Signal Transduction
  • Receptors, Antigen, B-Cell
  • Lymphocyte Activation
  • Linear Models
  • Immunization, Secondary
  • Humans
  • Half-Life
  • HIV-1